![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
R Loutzenhiser, K Hayashi and M Epstein
Nephrology Section, Veterans Administration Medical Center, Miami, Florida.
The intrarenal sites of action of atrial natriuretic peptide (ANP) have not been resolved fully. Although ANP relaxes in vitro preparations of smooth muscle and exerts profound effects on renal hemodynamics, the effects of ANP on resistance vessels remain a subject of controversy. In the present study, we utilized an in vitro perfused hydronephrotic rat kidney model to assess directly the actions of ANP on renal microvessels during norepinephrine (NE)-induced renal vasoconstriction. Perfusion pressure was maintained constant, and perfusate flow to the kidney was monitored while the afferent arteriole (AA) and efferent arteriole (EA) were visualized using videomicroscopy. Renal AA and EA diameters were measured by computer-assisted image analysis. NE (0.3 microM) decreased renal perfusate flow from 11.8 +/- 1.7 (S.E.) to 5.8 +/- 1.2 ml/min (P less than .005), decreased AA diameter from 20.2 +/- 0.7 to 14.3 +/- 0.8 mu (P less than .005) and decreased EA diameter from 18.6 +/- 1.2 to 15.1 +/- 1.2 mu (P less than .005). ANP (human ANF- (4-28), anaritide, Wyeth) completely reversed the NE-induced AA vasoconstriction with an IC50 of 9.3 +/- 5.6 nM. In contrast, ANP caused a further decrease in EA diameter at concentrations up to 10(-8) M, and elicited a slight dilation of the EA at 10(-7) M. In normal rat kidneys perfused under identical conditions, NE decreased renal perfusate flow, glomerular filtration rate and filtration fraction. ANP increased glomerular filtration rate and filtration fraction above control levels, with maximal effects at 10(-8) M.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  K. Hayashi, S. Wakino, N. Sugano, Y. Ozawa, K. Homma, and T. Saruta Ca2+ Channel Subtypes and Pharmacology in the Kidney Circ. Res., February 16, 2007; 100(3): 342 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. van Rodijnen, T. A. van Lambalgen, M. H. van Wijhe, G.-J. Tangelder, and P. M. ter Wee Renal microvascular actions of angiotensin II fragments Am J Physiol Renal Physiol, July 1, 2002; 283(1): F86 - F92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. van Rodijnen, T. A. van Lambalgen, G.-J. Tangelder, R. P.E. van Dokkum, A. P. Provoost, and P. M. ter Wee Reduced Reactivity of Renal Microvessels to Pressure and Angiotensin II in Fawn-Hooded Rats Hypertension, January 1, 2002; 39(1): 111 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ozawa, K. Hayashi, T. Nagahama, K. Fujiwara, and T. Saruta Effect of T-Type Selective Calcium Antagonist on Renal Microcirculation: Studies in the Isolated Perfused Hydronephrotic Kidney Hypertension, September 1, 2001; 38(3): 343 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F van Rodijnen, T. A van Lambalgen, M. E van Teijlingen, G.-J. Tangelder, and P. M ter Wee Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constriction Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S204 - S210. [Abstract] [PDF]
|
|
|
|
|
|
K. Loutzenhiser and R. Loutzenhiser Angiotensin II-Induced Ca2+ Influx in Renal Afferent and Efferent Arterioles : Differing Roles of Voltage-Gated and Store-Operated Ca2+ Entry Circ. Res., September 29, 2000; 87(7): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Reslerova and R. Loutzenhiser Renal microvascular actions of calcitonin gene-related peptide Am J Physiol Renal Physiol, June 1, 1998; 274(6): F1078 - F1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ter Wee, H. G. Forster, and M. Epstein Video-microscopic Assessment of the Role of Tissue Angiotensin-converting Enzyme in the Control of the Renal Microcirculation J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 434 - 439. [Abstract] [Full Text]
|
|
|
|
|
|
A. A. Seymour, M. M. Asaad, J. H. Sheldon, P. L. Smith, and W. L. Rogers Atrial Natriuretic Peptide in Chronically Hypertensive Dogs Hypertension, October 1, 1995; 26(4): 634 - 641. [Abstract] [Full Text]
|
|
|
|
|
|
K. Hayashi, H. Suzuki, and T. Saruta Nitric Oxide Modulates but Does Not Impair Myogenic Vasoconstriction of the Afferent Arteriole in Spontaneously Hypertensive Rats : Studies in the Isolated Perfused Hydronephrotic Kidney Hypertension, June 1, 1995; 25(6): 1212 - 1219. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
